ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.77 Million USD | 11.07% |
| 2022 | -8.74 Million USD | 6.93% |
| 2021 | -9.39 Million USD | 2.68% |
| 2020 | -9.65 Million USD | 34.17% |
| 2019 | -14.66 Million USD | -0.22% |
| 2018 | -14.63 Million USD | -45.79% |
| 2017 | -10.03 Million USD | -65.66% |
| 2016 | -6.05 Million USD | -4.67% |
| 2015 | -5.78 Million USD | -950.33% |
| 2014 | 680.81 Thousand USD | 106.74% |
| 2013 | -10.09 Million USD | -210.79% |
| 2012 | -3.24 Million USD | -18.92% |
| 2011 | -2.73 Million USD | 61.65% |
| 2010 | -7.12 Million USD | -402.69% |
| 2009 | -1.41 Million USD | 21.89% |
| 2008 | -1.81 Million USD | 19.42% |
| 2007 | -2.25 Million USD | 36.43% |
| 2006 | -3.54 Million USD | 40.55% |
| 2005 | -5.95 Million USD | -54.36% |
| 2004 | -3.85 Million USD | -613.55% |
| 2003 | -540.81 Thousand USD | -15667.26% |
| 2002 | -3430.00 USD | -66.91% |
| 2001 | -2055.00 USD | 43.09% |
| 2000 | -3611.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.23 Million USD | -544.23% |
| 2024 Q1 | -1.27 Million USD | 33.01% |
| 2023 Q1 | -1.97 Million USD | 25.28% |
| 2023 FY | -7.77 Million USD | 11.07% |
| 2023 Q4 | -1.9 Million USD | -4.58% |
| 2023 Q3 | -1.82 Million USD | 11.86% |
| 2023 Q2 | -2.07 Million USD | -4.94% |
| 2022 Q4 | -2.64 Million USD | -31.75% |
| 2022 FY | -8.74 Million USD | 6.93% |
| 2022 Q2 | -2.07 Million USD | -2.15% |
| 2022 Q3 | -2 Million USD | 3.26% |
| 2022 Q1 | -2.02 Million USD | 35.9% |
| 2021 Q3 | -1.93 Million USD | -4.81% |
| 2021 Q1 | -2.21 Million USD | -17.21% |
| 2021 Q4 | -3.16 Million USD | -63.58% |
| 2021 Q2 | -1.84 Million USD | 16.82% |
| 2021 FY | -9.39 Million USD | 2.68% |
| 2020 Q3 | -3.5 Million USD | -200.19% |
| 2020 Q2 | -1.16 Million USD | 54.12% |
| 2020 FY | -9.65 Million USD | 34.17% |
| 2020 Q1 | -2.54 Million USD | 38.45% |
| 2020 Q4 | -1.89 Million USD | 45.95% |
| 2019 Q4 | -4.13 Million USD | -131.98% |
| 2019 Q1 | -3.05 Million USD | 1.3% |
| 2019 Q2 | -2.54 Million USD | 16.91% |
| 2019 FY | -14.66 Million USD | -0.22% |
| 2019 Q3 | -1.78 Million USD | 29.88% |
| 2018 Q1 | -3.84 Million USD | 0.87% |
| 2018 Q3 | -4.11 Million USD | -15.28% |
| 2018 FY | -14.63 Million USD | -45.79% |
| 2018 Q4 | -3.09 Million USD | 24.8% |
| 2018 Q2 | -3.57 Million USD | 7.1% |
| 2017 FY | -10.03 Million USD | -65.66% |
| 2017 Q2 | -1.42 Million USD | 23.35% |
| 2017 Q1 | -1.86 Million USD | -51.14% |
| 2017 Q4 | -3.88 Million USD | -35.26% |
| 2017 Q3 | -2.86 Million USD | -100.95% |
| 2016 FY | -6.05 Million USD | -4.67% |
| 2016 Q4 | -1.23 Million USD | -8.05% |
| 2016 Q3 | -1.14 Million USD | 50.29% |
| 2016 Q2 | -2.29 Million USD | -64.64% |
| 2016 Q1 | -1.39 Million USD | -36.9% |
| 2015 Q2 | -2 Million USD | -56.13% |
| 2015 FY | -5.78 Million USD | -950.33% |
| 2015 Q4 | -1.01 Million USD | 30.99% |
| 2015 Q3 | -1.47 Million USD | 26.63% |
| 2015 Q1 | -1.28 Million USD | -277.24% |
| 2014 Q2 | -667.54 Thousand USD | -116.85% |
| 2014 Q1 | 3.96 Million USD | 1416.91% |
| 2014 FY | 680.81 Thousand USD | 106.74% |
| 2014 Q4 | 726.25 Thousand USD | 121.74% |
| 2014 Q3 | -3.34 Million USD | -400.37% |
| 2013 Q4 | 261.21 Thousand USD | 105.58% |
| 2013 Q3 | -4.68 Million USD | 1.45% |
| 2013 Q2 | -4.74 Million USD | -412.28% |
| 2013 FY | -10.09 Million USD | -210.79% |
| 2013 Q1 | -927.1 Thousand USD | -5.22% |
| 2012 Q4 | -881.07 Thousand USD | -57.32% |
| 2012 Q2 | -748.55 Thousand USD | 29.3% |
| 2012 Q3 | -560.06 Thousand USD | 25.18% |
| 2012 FY | -3.24 Million USD | -18.92% |
| 2012 Q1 | -1.05 Million USD | 24.85% |
| 2011 Q4 | -1.4 Million USD | -159.76% |
| 2011 Q1 | -467.28 Thousand USD | 94.51% |
| 2011 Q2 | -313.17 Thousand USD | 32.98% |
| 2011 Q3 | -542.35 Thousand USD | -73.18% |
| 2011 FY | -2.73 Million USD | 61.65% |
| 2010 Q1 | -5.49 Million USD | -908.68% |
| 2010 Q2 | 7.47 Million USD | 236.07% |
| 2010 Q3 | -589.07 Thousand USD | -107.88% |
| 2010 Q4 | -8.51 Million USD | -1345.65% |
| 2010 FY | -7.12 Million USD | -402.69% |
| 2009 Q2 | -333.34 Thousand USD | 51.06% |
| 2009 Q4 | 679.75 Thousand USD | 162.82% |
| 2009 Q3 | -1.08 Million USD | -224.62% |
| 2009 FY | -1.41 Million USD | 21.89% |
| 2009 Q1 | -681.16 Thousand USD | -79.02% |
| 2008 Q3 | -266.45 Thousand USD | 46.65% |
| 2008 Q1 | -667.41 Thousand USD | -36.75% |
| 2008 FY | -1.81 Million USD | 19.42% |
| 2008 Q2 | -499.48 Thousand USD | 25.16% |
| 2008 Q4 | -380.48 Thousand USD | -42.8% |
| 2007 Q4 | -488.04 Thousand USD | 29.57% |
| 2007 Q1 | -613.51 Thousand USD | 18.29% |
| 2007 Q2 | -456.49 Thousand USD | 25.59% |
| 2007 Q3 | -692.93 Thousand USD | -51.79% |
| 2007 FY | -2.25 Million USD | 36.43% |
| 2006 FY | -3.54 Million USD | 40.55% |
| 2006 Q2 | -1.18 Million USD | -22.77% |
| 2006 Q3 | -634.55 Thousand USD | 46.59% |
| 2006 Q4 | -750.82 Thousand USD | -18.32% |
| 2006 Q1 | -967.73 Thousand USD | -8.46% |
| 2005 Q2 | -317 Thousand USD | 10.81% |
| 2005 Q4 | -892.23 Thousand USD | 79.69% |
| 2005 Q1 | -355.41 Thousand USD | 36.08% |
| 2005 FY | -5.95 Million USD | -54.36% |
| 2005 Q3 | -4.39 Million USD | -1285.54% |
| 2004 Q2 | -739.1 Thousand USD | 54.18% |
| 2004 FY | -3.85 Million USD | -613.55% |
| 2004 Q4 | -556.03 Thousand USD | 41.52% |
| 2004 Q1 | -1.61 Million USD | -199.95% |
| 2004 Q3 | -950.74 Thousand USD | -28.64% |
| 2003 Q2 | -561.00 USD | 70.4% |
| 2003 FY | -540.81 Thousand USD | -15667.26% |
| 2003 Q4 | -537.8 Thousand USD | -95764.53% |
| 2003 Q1 | -1895.00 USD | -237.79% |
| 2003 Q3 | -561.00 USD | 0.0% |
| 2002 Q2 | -597.00 USD | 63.46% |
| 2002 Q1 | -1634.00 USD | -166.56% |
| 2002 FY | -3430.00 USD | -66.91% |
| 2002 Q4 | -561.00 USD | 12.07% |
| 2002 Q3 | -638.00 USD | -6.87% |
| 2001 Q2 | -620.00 USD | -196.65% |
| 2001 Q4 | -613.00 USD | 0.0% |
| 2001 FY | -2055.00 USD | 43.09% |
| 2001 Q3 | -613.00 USD | 1.13% |
| 2001 Q1 | -209.00 USD | 90.62% |
| 2000 Q4 | -2228.00 USD | -257.62% |
| 2000 Q2 | -460.00 USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | -3611.00 USD | 0.0% |
| 2000 Q3 | -623.00 USD | -35.43% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | -15.23 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -921.405% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 9.903% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 74.708% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 93.734% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 51.628% |
| Better Therapeutics, Inc. | -39.76 Million USD | 80.44% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 58.777% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 57.682% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 78.283% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 78.436% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 93.209% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -245.92% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 89.596% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 86.837% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -29.874% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 63.477% |
| Molecular Templates, Inc. | -8.12 Million USD | 4.269% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 48.757% |
| NexImmune, Inc. | -32.34 Million USD | 75.955% |
| Orgenesis Inc. | -55.36 Million USD | 85.952% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 69.215% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -9868.576% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 57.478% |
| Scopus BioPharma Inc. | -11.6 Million USD | 33.012% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.642% |
| Statera Biopharma, Inc. | -174.4 Million USD | 95.541% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -116.755% |
| Trevena, Inc. | -40.28 Million USD | 80.697% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -13559.999% |
| Vaccinex, Inc. | -20.25 Million USD | 61.596% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -557.906% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 84.768% |